Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody

Ziduo Li; Edward Abadir; Kenneth Lee; Candice Clarke; Christian E. Bryant; Wendy Cooper; Geoffrey Pietersz; James Favaloro; Pablo A. Silveira; Derek N. J. Hart; Xinsheng Ju; Georgina J. Clark

doi:10.1002/cti2.1156

Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody

Ziduo Li, Edward Abadir, Kenneth Lee, Candice Clarke, Christian E. Bryant, Wendy Cooper, Geoffrey Pietersz, James Favaloro, Pablo A. Silveira, Derek N. J. Hart, Xinsheng Ju, Georgina J. Clark

Western Sydney University

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

2 Downloads (Pure)

Abstract

Objectives: Effective antibody–drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma. Our objective was to determine CD83 expression on non-Hodgkin lymphoma (NHL) and its therapeutic potential to treat mantle cell lymphoma (MCL) which is currently an incurable NHL. Methods: We analysed CD83 expression on MCL cell lines and the lymph node/bone marrow biopsies of MCL patients. We tested the killing effect of CD83 ADC in vitro and in an in vivo xenograft MCL mouse model. Results: CD83 is expressed on MCL, and its upregulation is correlated with the nuclear factor κB (NF-κB) activation. CD83 ADC kills MCL in vitro and in vivo. Doxorubicin and cyclophosphamide (CP), which are included in the current treatment regimen for MCL, enhance the NF-κB activity and increase CD83 expression on MCL cell lines. The combination of CD83 ADC with doxorubicin and CP has synergistic killing effect of MCL. Conclusion: This study provides evidence that a novel immunotherapeutic agent CD83 ADC, in combination with chemotherapy, has the potential to enhance the efficacy of current treatments for MCL.

Original language	English
Article number	e1156
Number of pages	12
Journal	Clinical and Translational Immunology
Volume	9
Issue number	7
DOIs	https://doi.org/10.1002/cti2.1156
Publication status	Published - Jan 2020

Bibliographical note

Publisher Copyright:
© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.

Open Access - Access Right Statement

This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cti2.1156

Open Access

Cite this

@article{f5239b2760ad4ab38547e9f1223e2931,

title = "Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody",

abstract = "Objectives: Effective antibody–drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma. Our objective was to determine CD83 expression on non-Hodgkin lymphoma (NHL) and its therapeutic potential to treat mantle cell lymphoma (MCL) which is currently an incurable NHL. Methods: We analysed CD83 expression on MCL cell lines and the lymph node/bone marrow biopsies of MCL patients. We tested the killing effect of CD83 ADC in vitro and in an in vivo xenograft MCL mouse model. Results: CD83 is expressed on MCL, and its upregulation is correlated with the nuclear factor κB (NF-κB) activation. CD83 ADC kills MCL in vitro and in vivo. Doxorubicin and cyclophosphamide (CP), which are included in the current treatment regimen for MCL, enhance the NF-κB activity and increase CD83 expression on MCL cell lines. The combination of CD83 ADC with doxorubicin and CP has synergistic killing effect of MCL. Conclusion: This study provides evidence that a novel immunotherapeutic agent CD83 ADC, in combination with chemotherapy, has the potential to enhance the efficacy of current treatments for MCL.",

author = "Ziduo Li and Edward Abadir and Kenneth Lee and Candice Clarke and Bryant, {Christian E.} and Wendy Cooper and Geoffrey Pietersz and James Favaloro and Silveira, {Pablo A.} and Hart, {Derek N. J.} and Xinsheng Ju and Clark, {Georgina J.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.",

year = "2020",

month = jan,

doi = "10.1002/cti2.1156",

language = "English",

volume = "9",

journal = "Clinical and Translational Immunology",

issn = "2050-0068",

publisher = "John Wiley & Sons",

number = "7",

}

TY - JOUR

T1 - Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody

AU - Li, Ziduo

AU - Abadir, Edward

AU - Lee, Kenneth

AU - Clarke, Candice

AU - Bryant, Christian E.

AU - Cooper, Wendy

AU - Pietersz, Geoffrey

AU - Favaloro, James

AU - Silveira, Pablo A.

AU - Hart, Derek N. J.

AU - Ju, Xinsheng

AU - Clark, Georgina J.

PY - 2020/1

Y1 - 2020/1

N2 - Objectives: Effective antibody–drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma. Our objective was to determine CD83 expression on non-Hodgkin lymphoma (NHL) and its therapeutic potential to treat mantle cell lymphoma (MCL) which is currently an incurable NHL. Methods: We analysed CD83 expression on MCL cell lines and the lymph node/bone marrow biopsies of MCL patients. We tested the killing effect of CD83 ADC in vitro and in an in vivo xenograft MCL mouse model. Results: CD83 is expressed on MCL, and its upregulation is correlated with the nuclear factor κB (NF-κB) activation. CD83 ADC kills MCL in vitro and in vivo. Doxorubicin and cyclophosphamide (CP), which are included in the current treatment regimen for MCL, enhance the NF-κB activity and increase CD83 expression on MCL cell lines. The combination of CD83 ADC with doxorubicin and CP has synergistic killing effect of MCL. Conclusion: This study provides evidence that a novel immunotherapeutic agent CD83 ADC, in combination with chemotherapy, has the potential to enhance the efficacy of current treatments for MCL.

AB - Objectives: Effective antibody–drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma. Our objective was to determine CD83 expression on non-Hodgkin lymphoma (NHL) and its therapeutic potential to treat mantle cell lymphoma (MCL) which is currently an incurable NHL. Methods: We analysed CD83 expression on MCL cell lines and the lymph node/bone marrow biopsies of MCL patients. We tested the killing effect of CD83 ADC in vitro and in an in vivo xenograft MCL mouse model. Results: CD83 is expressed on MCL, and its upregulation is correlated with the nuclear factor κB (NF-κB) activation. CD83 ADC kills MCL in vitro and in vivo. Doxorubicin and cyclophosphamide (CP), which are included in the current treatment regimen for MCL, enhance the NF-κB activity and increase CD83 expression on MCL cell lines. The combination of CD83 ADC with doxorubicin and CP has synergistic killing effect of MCL. Conclusion: This study provides evidence that a novel immunotherapeutic agent CD83 ADC, in combination with chemotherapy, has the potential to enhance the efficacy of current treatments for MCL.

UR - https://hdl.handle.net/1959.7/uws:65202

U2 - 10.1002/cti2.1156

DO - 10.1002/cti2.1156

M3 - Article

SN - 2050-0068

VL - 9

JO - Clinical and Translational Immunology

JF - Clinical and Translational Immunology

IS - 7

M1 - e1156

ER -

Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody

Abstract

Bibliographical note

Open Access - Access Right Statement

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this